Assisted reproductive technologies in conjunction with conservatively treated endometrial adenocarcinoma. A case report.

Abstract

This case report illustrates the successful use of assisted reproductive technologies (ARTs) in a patient receiving conservative treatment for endometrial adenocarcinoma. A 31-year-old infertile woman, diagnosed as FIGO stage Ia endometrial adenocarcinoma (grade 1), received oral medroxyprogesterone acetate 400 mg/day for 12 weeks. Endometrial curettage was performed and the absence of endometrial carcinoma was confirmed. A single pregnancy was achieved with in vitro fertilization and embryo transfer. A healthy female infant was born via cesarean section at 42 weeks' gestation. The carcinoma has not recurred, and the patient now desires a second child. We conclude that ART combined with progesterone treatment might be a powerful option for the treatment of infertile patients with early stage, well-differentiated endometrial adenocarcinoma.

• Authors: S Ogawa, T Koike, H Shibahara, M Ohwada, M Suzuki, S Araki, I Sato
• Journal: Gynecologic and obstetric investigation (Gynecol Obstet Invest) Vol. 51 Issue 3 Pg. 214-6 ( 2001) ISSN: 0378-7346 [Print] Switzerland
• PMID: 11306913 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2001 S. Karger AG, Basel

Chemical References

• Medroxyprogesterone Acetate

Topics

• Adenocarcinoma (complications, drug therapy, pathology)
• Adult
• Curettage
• Endometrial Neoplasms (complications, drug therapy, pathology)
• Female
• Gamete Intrafallopian Transfer
• Humans
• Infertility, Female (complications, therapy)
• Medroxyprogesterone Acetate (therapeutic use)
• Pregnancy
• Pregnancy Outcome